1차 출처 기록
결정급탑라인 결과
Praxis: EMBRAVE Part A 톱라인, elsunersen으로 발작 77% 감소 확인
The 8-K discloses positive Phase 1/2 EMBRAVE Part A topline results for elsunersen in SCN2A DEE, including 77% placebo-adjusted seizure reduction and 100% functional improvement. The same filing also notes FDA priority-review acceptance of relutrigine NDA with a September 27, 2026 PDUFA date.
핵심 사실
출처 발췌
prax-20260406 FALSE 0001689548 0001689548 2026-04-06 2026-04-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2026 PRAXIS PRECISION MEDICINES, INC. (Exact name of registrant as specified in its charter) Delaware 001-39620 47-5195942 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Praxis Precision Medicines, Inc. 99 High Street , 30th Floor Boston , Massachusetts 02110 (Address of principal executive offices, including zip code) ( 617 ) 300-8460 (Registrant’s telephone number, including area code) Not Applicable (Former Name or Former Address, if